Bioqual (BIOQ) Stock Price
Bioqual Price
Revenue has compounded at 4.1% per year over the past 22 years to 39.95 M USD. Earnings per share have declined at 1.7% per year over the last 20 years. Bioqual's net margin stands at -10.4%, down from 8.0% several years earlier. Bioqual currently offers a dividend yield of about 1.52%. The payout ratio is around 54% of earnings. The dividend has grown at 8.3% per year over the past 19 years.
Bioqual stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Bioqual business model & stock analysis
Frequently asked questions about Bioqual
The business model of Bioqual Inc is to provide contract research services to biotechnology and pharmaceutical companies, government agencies, and academic institutions. Bioqual specializes in preclinical and clinical research, including animal model development, in vitro testing, and regulatory compliance. Through collaboration with clients, Bioqual aims to advance the development of drugs, vaccines, and therapeutics, ultimately contributing to the improvement of human and animal health. With its expertise and state-of-the-art facilities, Bioqual Inc has established itself as a trusted partner in the biomedical research industry.
Bioqual Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Bioqual Inc in the market include Company A, Company B, and Company C. These companies operate in the same industry and offer similar products and services to Bioqual Inc. Their competitive presence challenges Bioqual Inc's market position and drives innovation within the industry. Maintaining a competitive edge is crucial for Bioqual Inc to attract and retain customers, expand its market share, and achieve long-term success. As Bioqual Inc continues to navigate its way in the market, it recognizes the importance of monitoring and adapting to the strategies and offerings of its key competitors.
Bioqual Inc. is a reputable company with a rich history and background. Established in [year], Bioqual Inc. has been a leading player in the [industry] sector. The company specializes in [specific products/services] and has built a strong reputation for its commitment to innovation, quality, and customer satisfaction. With a team of experienced professionals and state-of-the-art facilities, Bioqual Inc. has consistently delivered outstanding results and garnered recognition for its contributions to [industry]. Over the years, Bioqual Inc. has expanded its presence globally and continues to be a trusted name in the [industry] market, providing sustainable solutions and driving advancements in [industry].
Bioqual Inc has achieved several significant milestones over the years. The company has successfully gained recognition as a leading biomedical research organization, specializing in preclinical and clinical testing services. Notably, Bioqual Inc has garnered a strong reputation for its contributions to drug development, infectious disease research, and vaccine testing. The company has also established numerous strategic partnerships with pharmaceutical and biotech companies, academia, and government agencies. Furthermore, Bioqual Inc has consistently demonstrated exceptional scientific expertise, state-of-the-art facilities, and a commitment to quality, making it a trusted name in the industry.
Bioqual Inc is primarily present in the United States.
Bioqual Inc represents a commitment to excellence in the field of biomedical research. With a strong emphasis on animal modeling and preclinical testing services, Bioqual is dedicated to paving the way for breakthrough discoveries in healthcare and life sciences. The company's corporate philosophy revolves around comprehensive expertise, innovative solutions, and ensuring the highest standards of animal welfare. By providing state-of-the-art facilities and a team of skilled professionals, Bioqual strives to support scientific advancements and contribute to the development of novel therapies and vaccines. With a focus on quality, reliability, and integrity, Bioqual Inc is trusted by leading pharmaceutical and biotechnology companies worldwide.
Converted at the current exchange rate, the Bioqual share trades at 29.35 EUR (33.00 USD).
Bioqual Inc is a US-based company specializing in providing research services and products for the life sciences, pharmaceuticals, and biotechnology industries. The company was founded in 1981 and has been offering innovative solutions to its customers since then.
The revenue of Bioqual is 39.95 M USD. This figure is based on current financial data and reflects the company's business performance.
The profit of Bioqual is -4.17 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Bioqual is currently -7.08. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Bioqual stock.
The price-to-sales ratio (P/S) of Bioqual is currently 0.74. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Bioqual stock.
The Eulerpool Quality Score for Bioqual is 1/10.
The ISIN of Bioqual is US09065J1016. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Bioqual is BIOQ. The ticker symbol is used to trade Bioqual shares on the stock exchange.
Bioqual stock
Bioqual FIGI
All fundamentals and in-depth analysis of Bioqual
Our stock analysis for Bioqual stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bioqual. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.